Autolus Therapeutics Ltd – (NASDAQ:AUTL)’s stock price shot up 11.9% on Monday . The stock traded as high as $15.82 and last traded at $15.38, 128,906 shares changed hands during trading. An increase of 34% from the average session volume of 96,501 shares. The stock had previously closed at $13.75.

Several research firms have weighed in on AUTL. HC Wainwright set a $18.00 target price on Sutro Biopharma and gave the company a “buy” rating in a research note on Friday, May 17th. Zacks Investment Research raised General Moly from a “sell” rating to a “hold” rating in a research note on Thursday, July 11th. Finally, William Blair began coverage on American Software in a research note on Wednesday, April 3rd. They set an “outperform” rating and a $12.03 target price on the stock.

The company has a debt-to-equity ratio of 0.12, a quick ratio of 10.66 and a current ratio of 10.66. The stock’s 50 day moving average price is $15.69. The firm has a market capitalization of $552.01 million and a P/E ratio of -10.83.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.69) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.11). The company had revenue of $1.96 million during the quarter, compared to analyst estimates of $0.30 million. Sell-side analysts anticipate that Autolus Therapeutics Ltd – will post -3.07 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP grew its stake in shares of Autolus Therapeutics by 93.4% in the 1st quarter. Marshall Wace LLP now owns 232,931 shares of the company’s stock valued at $7,330,000 after buying an additional 112,489 shares in the last quarter. BlackRock Inc. grew its stake in shares of Autolus Therapeutics by 4,011.3% in the 4th quarter. BlackRock Inc. now owns 202,973 shares of the company’s stock valued at $6,666,000 after buying an additional 198,036 shares in the last quarter. CWM LLC bought a new stake in shares of Autolus Therapeutics in the 1st quarter valued at approximately $1,105,000. Geode Capital Management LLC bought a new stake in shares of Autolus Therapeutics in the 4th quarter valued at approximately $322,000. Finally, Barclays PLC bought a new stake in shares of Autolus Therapeutics in the 4th quarter valued at approximately $113,000. 43.38% of the stock is owned by institutional investors and hedge funds.

About Autolus Therapeutics (NASDAQ:AUTL)

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.

Featured Article: How to Invest in the Dividend Aristocrat Index

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.